Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Turner's Syndrome
Conditions
Turner's Syndrome
Trial Timeline
Apr 1, 2009 → Mar 1, 2011
NCT ID
NCT00870220About Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch
Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch is a phase 1 stage product being developed by Novo Nordisk for Turner's Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT00870220. Target conditions include Turner's Syndrome.
What happened to similar drugs?
1 of 1 similar drugs in Turner's Syndrome were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00870220 | Phase 1 | Terminated |
Competing Products
1 competing product in Turner's Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| r-hGH | Merck | Approved | 43 |